RBC Capital analyst Deane Dray raised the firm’s price target on Emerson (EMR) to $176 from $153 and keeps an Outperform rating on the shares. The firm cites the company’s Q1 beat while noting that strong orders, backlog growth, and project funnel visibility underlie confidence in the second-half implied growth ramp, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMR: